You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 16, 2026

Profile for Poland Patent: 4327804


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Poland Patent: 4327804

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Apr 22, 2036 Xeris GVOKE HYPOPEN glucagon
⤷  Start Trial Apr 22, 2036 Xeris GVOKE KIT glucagon
⤷  Start Trial Apr 22, 2036 Xeris GVOKE PFS glucagon
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Patent Landscape and Scope for Poland Patent PL4327804

Last updated: April 16, 2026

What does patent PL4327804 cover?

Patent Title: Not specified in the request; assuming it relates to a pharmaceutical invention.

Application Filing Date: Exact date not provided; presumed to be recent or relevant to current patent expiry timelines.

Patent Number: PL4327804

Patent Type: National patent granted in Poland

Priority Claims: Typically, Polish patents claim priority from a prior international (PCT) or regional application, influencing scope and potential territorial reach.

Current Status: Presumably granted; confirmation needed via Polish Patent Office records.

What are the scope and claims of PL4327804?

Claim structure and scope

  • The patent contains a series of claims defining the invention's scope; these may include independent and dependent claims.
  • Usually, primary claims cover the core pharmaceutical compound, formulation, or method of use.

Claim analysis

Claim Type Expected Content Typical Language
Independent Claims Cover the novel compound or method of treatment. "A pharmaceutical composition comprising..."
Dependent Claims Specify particular embodiments, embodiments, or modifications. "The composition of claim 1, wherein..."
  • Claims likely specify the chemical structure, process of manufacturing, dosage regimen, or medical application.
  • The claims may be broad, covering various derivatives or formulations, or narrow, focusing on specific compounds or methodologies.

Key claim elements (hypothetical based on typical pharma patents)

  • Chemical formula or structural claim
  • Method of production
  • Therapeutic use or indication
  • Packaging or delivery system

Patent landscape in Poland and broader relevance

Polish patent system specifics

  • Filed with the Polish Patent Office (UPRP); grants are published typically within 3–4 years of filing.
  • Patent term: 20 years from the filing date, subject to annuities.
  • Patentability criteria: Novelty, inventive step, industrial applicability.

Landscape considerations

  • The patent landscape depends on claims scope, prior art, and concurrent pending applications.
  • Poland is part of the European patent system; cross-referencing claims with EPO filings can identify broader protection.

Regional and global relevance

  • Check for equivalent applications in the European Patent Office (EPO) or World Intellectual Property Organization (WIPO).
  • Patent families extending to key markets such as the EU, US, or Asia improve commercialization scope.

Competitive landscape

  • Identify similar inventions filed within Europe or globally.
  • Patent searches reveal competing patents, potential infringement risks, or freedom-to-operate assessments.

Key patentability and enforceability considerations

  • Claims' breadth: Enforcing broad claims depends on their novelty and inventive step compared to prior art.
  • Prior art search: Must include recent pharmaceutical patents, scientific publications, and known compounds.
  • Opposition and invalidation: Competitors may challenge the patent's validity based on prior disclosures or obviousness.

Timeline and procedural aspects

  • Estimated filing to grant duration: 3–4 years.
  • Maintenance fees: Due annually; failure results in patent lapse.
  • Opportunities for opposition: Typically within 9 months after grant (post-grant opposition).

Summary

Patent PL4327804 likely covers a specific pharmaceutical compound or method with claims defining its structural or functional aspects. Its scope will influence licensing, commercialization, or infringement risk in Poland and potentially in wider jurisdictions via patent family extensions. The patent's validity depends on the breadth of claims relative to prior art, which requires ongoing vigilance.

Key Takeaways

  • Verify the specific claims and scope via the Polish Patent Office or official patent documents.
  • Cross-reference with EPO and WIPO filings to assess regional coverage.
  • Broader protection depends on patent family strategies and subsequent filings.
  • Competitor patent activity must be monitored to manage infringement risks.
  • Patent maintenance and potential oppositions can influence the patent lifecycle.

FAQs

1. How can I access the detailed claims of PL4327804?
Official patent documents are available from the Polish Patent Office (UPRP) or through patent databases such as Espacenet.

2. What is the enforceability of patents in Poland?
Polish patents are enforceable within Poland; enforceability in other jurisdictions requires corresponding patents or applications.

3. How does patent scope affect licensing strategies?
Broader claims enable wider licensing options but are more susceptible to invalidation. Narrower claims provide limited coverage but are easier to defend.

4. Can the patent be challenged or invalidated?
Yes; opposition procedures and invalidity claims can be filed based on prior art or lack of inventive step.

5. How does patent protection in Poland compare with the EU or US?
While Poland grants national patents, applicants can seek broader protection via the European Patent Convention (EPC) or direct US filings, extending patent rights regionally or globally.


References

[1] Polish Patent Office. (2023). Patent database.
[2] European Patent Office. (2023). Patent search tools.
[3] World Intellectual Property Organization. (2023). Patent information services.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.